PRESS RELEASE published on 09/23/2024 at 17:51, 1 year 8 months ago AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024 AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024, showing promising results in phase 2B/3 study AB07002 Phase 3 Study AB Science Masitinib ECTRIMS 2024 Progressive Multiple Sclerosis
BRIEF published on 07/08/2024 at 08:01, 1 year 11 months ago AB Science Announces Positive Results of Phase 2 Study for Masitinib in COVID-19 COVID-19 Clinical Trial Phase 2 Study AB Science Masitinib
BRIEF published on 07/08/2024 at 08:01, 1 year 11 months ago AB Science annonce les résultats positifs de l'étude de phase 2 sur le masitinib dans le traitement du COVID-19 Essai Clinique Étude De Phase 2 COVID 19 AB Science Masitinib
PRESS RELEASE published on 07/08/2024 at 07:56, 1 year 11 months ago AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19 AB Science reports positive results of its phase 2 study evaluating masitinib in COVID-19, showing improved clinical status in hospitalized patients. Study indicates potential for masitinib as a COVID-19 treatment COVID-19 Treatment Phase 2 Study AB Science Masitinib
PRESS RELEASE published on 07/08/2024 at 07:56, 1 year 11 months ago AB Science annonce des résultats positifs de son étude de Phase 2 évaluant le masitinib dans la Covid-19 AB Science annonce des résultats positifs de son étude de phase 2 évaluant le masitinib dans la COVID-19. Les analyses montrent un potentiel traitement prometteur pour les patients hospitalisés COVID-19 Traitement Étude De Phase 2 AB Science Masitinib
BRIEF published on 06/28/2024 at 12:36, 1 year 11 months ago AB Science fait le point sur la demande d'autorisation du masitinib dans la SLA Autorisation De Mise Sur Le Marché AB Science Masitinib EMA SLA
BRIEF published on 06/28/2024 at 12:36, 1 year 11 months ago AB Science provides an update on the application for authorization of masitinib in ALS ALS AB Science Masitinib EMA Marketing Authorization
PRESS RELEASE published on 06/28/2024 at 12:31, 1 year 11 months ago AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA AB Science annonce un avis négatif sur la demande de mise sur le marché du masitinib dans la SLA et prévoit un réexamen du dossier. Détails sur les raisons et les prochaines étapes AB Science Masitinib Sclérose Latérale Amyotrophique Autorisation Conditionnelle Réexamen Dossier
PRESS RELEASE published on 06/28/2024 at 12:31, 1 year 11 months ago AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS AB Science receives negative opinion from CHMP on masitinib's conditional marketing authorization for ALS treatment but plans re-examination due to urgent patient need and safety considerations AB Science Masitinib CHMP ALS Treatment Conditional Marketing Authorization
BRIEF published on 06/27/2024 at 10:20, 1 year 11 months ago AB Science - Résultats de l'Assemblée Générale Mixte du 26 juin 2024 Actionnaires Capital Social Assemblée Générale Resolutions AB Science
Published on 06/19/2026 at 04:30, 19 hours 3 minutes ago Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 22 hours 13 minutes ago American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 22 hours 26 minutes ago Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting
Published on 06/19/2026 at 00:00, 23 hours 33 minutes ago Redwood AI Announces Initiation of Chemical Risk Assessment Module
Published on 06/19/2026 at 20:17, 3 hours 15 minutes ago 2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Published on 06/19/2026 at 20:17, 3 hours 15 minutes ago 2CRSi SA: 2CRSi répond point par point au rapport de Grizzly Research et réaffirme la réalité de son activité
Published on 06/19/2026 at 19:01, 4 hours 32 minutes ago Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting
Published on 06/19/2026 at 19:33, 4 hours ago Déclaration hebdomadaire d'opérations effectuées du 15 au 19 juin 2026
Published on 06/19/2026 at 19:33, 4 hours ago Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 4 hours 9 minutes ago Imerys-06-2026-communique-capital-droits-de-vote-au-31-mai-2026
Published on 06/19/2026 at 19:23, 4 hours 9 minutes ago Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026